1. Pavy-Le Traon A, Saivin S, Soulez-LaRiviere C, Pujos M, Guell A, Houin G. Pharmacology in space: pharmacotherapy. Adv Space Biol Med. 1997;6:93–105.
2. Stingl JC, Welker S, Hartmann G, Damann V, Gerzer R. Where failure is not an option -personalized medicine in astronauts. PLoS One. 2015;10:e0140764.
3. Antonsen, E., Bayuse, T., Blue, R., Daniels, V., Hailey, M., Hussey, S., et al. Evidence report: risk of adverse health outcomes and decrements in performance due to in-flight medical conditions. National Aeronautics and Space Administration, Houston, Tx, USA. Approved for public release: May 8, 2017. Available at:
https://humanresearchroadmap.nasa.gov/risks/risk.aspx?i=95
. Accessed: March 30, 2019.
4. Barger LK, Flynn-Evans EE, Kubey A, Walsh L, Ronda JM, Wang W, et al. Prevalence of sleep deficiency and use of hypnotic drugs in astronauts before, during, and after spaceflight: an observational study. Lancet Neurol. 2014;13:904–12.
5. Putcha L, Berens KL, Marshburn TH, Ortega HJ, Billica RD. Pharmaceutical use by U.S. astronauts on space shuttle missions. Aviat Space Environ Med. 1999;70:705–8.